Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation
July 28, 2025
The Listing Department, National Stock Exchange of India Limited NSE Symbol: VIJAYA
The Corporate Relations Department, BSE Limited BSE Scrip Code: 543350
Dear Sir/Madam,
Sub: Investor Presentation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation on Financial Results for first quarter ended June 30, 2025, which would be used in the Investors / Analysts earnings conference call scheduled to be held on July 28, 2025, at 05:00 P.M. (IST).
Please take the information on record.
Thanking you, For Vijaya Diagnostic Centre Limited
Hansraj Singh Company Secretary & Compliance Officer M. No. F11438
Encl.: As Above
Q1 FY26 Earnings Presentation
July 28, 2025
Q2 & H1 FY25 Earnings Presentation, November 07, 2024
Safe Harbour
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.
All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.
2
Strategic Expansion
Q1 FY26 Performance Snapshot
Q1 FY26 Performance Snapshot
Financial Performance
Key Metrics
INR 1,881 Mn Revenue from Operations
INR 735 Mn | 39.1% EBITDA | EBITDA Margin %
INR 383 Mn | 20.4% PAT | PAT Margin %
1.10 Mn
Footfall
157 (1)
Centres
3.94 Mn
Tests
93%
B2C Revenue %
YOY Growth %
Geographical Contribution
Wellness Share%
20.4%
16.7%
14.4%
Revenue Growth %
Test Volume Growth %
Footfall Growth %
3%2%
6%
19%
70%
14.2%
Hyderabad
RoAPT
Pune
Kolkata
Others
Welness Share %
1. Total number of centres as at 30-Jun-25
4
Management Commentary
“ Vijaya reported another strong financial quarter, achieving a YOY growth of 20.4%, with our Hyderabad market returning to double-digit growth this quarter. The strong performance was
largely driven by volume and change in the test mix.
I'm happy to state that all the new hubs in Pune, Bengaluru, and West Bengal are up and running,
with steady footfall. We remain optimistic about achieving break-even across all centres within
the 12 months with 1 hub centre in Bengaluru on track to reach break-even earlier than the
estimated timeline.
Commenting on the Q1 FY26 results and future business outlook, Ms. Suprita Reddy, MD & CEO at Vijaya Diagnostic Centre Ltd. said:
I’m also pleased to share that our Nizamabad hub centre has achieved break-even within 2
quarters of its full-fledged operations.
Looking ahead, we would be commissioning 3 hubs in Q2 FY26 across our Core Geography and ” West Bengal. The other 2 hubs in West Bengal are also on track to be operationalized by H2 FY26.
5
Key Financial Highlights – Q1 FY26
Revenue from Operations (INR Mn)
EBITDA & EBITDA Margin %
PAT & PAT Margin %
Key
Financials
1,562
1,732
1,881
6,814
5,478
39.2%
39.8%
39.1%
40.3%
40.1%
20.1%
20.0%
20.4%
21.7%
21.0%
2,732
2,209
1,431
1,188
612
689
735
313
346
383
Q1 FY25 Q4 FY25 Q1 FY26
FY24
FY25
Q1 FY25
Q4 FY25
Q1 FY26
FY24
FY25
Q1 FY25
Q4 FY25
Q1 FY26
FY24
FY25
Radiology vs. Pathology Breakdown %
B2C Revenue %
Wellness share %
Radiology
Pathology
Revenue
Mix
62%
62%
61%
64%
63%
93%
93%
93%
94%
93%
13.4%
15.0%
14.2%
12.9%
14.1%
38%
38%
39%
36%
37%
Q1 FY25 Q4 FY25 Q1 FY26
FY24
FY25
Q1 FY25
Q4 FY25
Q1 FY26
FY24
FY25
Q1 FY25
Q4 FY25
Q1 FY26
FY24
FY25
6
Key Operational Highlights
Tests Performed (# in Mn)
Footfalls (# in Mn)
Tests / Footfalls (# in Mn)
14.79
11.89
4.19
3.55
3.62
3.58
3.51
3.38
3.79
3.94
0.96
1.05
1.10
3.53
3.35
Q1 FY25
Q4 FY25
Q1 FY26
FY24
FY25
Q1 FY25
Q4 FY25
Q1 FY26
FY24
FY25
Q1 FY25
Q4 FY25
Q1 FY26
FY24
FY25
Revenue per Test (INR)
Revenue per Footfall (INR)
477
462
457
461
461
1,621
1,655
1,707
1,627
1,543
Q1 FY25
Q4 FY25
Q1 FY26
FY24
FY25
Q1 FY25
Q4 FY25
Q1 FY26
FY24
FY25
7
Consolidated Profit & Loss Statement
Particulars
Q1 FY26
Q1 FY25
Y-o-Y
Q4 FY25
Q-o-Q
Revenue from operations
1,880.5
1,562.2
Cost of materials consumed
Employee benefits expense
Other expenses
EBITDA
EBITDA Margin (%)
Other income
Depreciation and amortization expense
EBIT
Finance costs
Profit before Exceptional Items & Tax
Exceptional Items
Profit before Tax
Tax expenses
Profit before Minority Interest
Minority Interest
Profit after Tax (PAT)
PAT Margin (%)
EPS – Basic (INR)
214.1
316.1
615.0
735.3
187.6
273.6
488.6
612.4
20.4%
14.2%
15.5%
25.9%
20.1%
39.1%
39.2%
-10BPS
70.5
208.9
596.9
74.9
522.1
-
522.1
136.2
385.9
2.5
383.4
20.4%
3.8 *
35.6
166.3
481.7
62.7
419.0
-
419.0
104.0
315.1
1.6
313.5
20.1%
3.1 *
97.8%
25.6%
23.9%
19.5%
24.6%
-
24.6%
31.0%
22.5%
56.4%
22.3%
32BPS
22.9%
1,732.4
221.7
284.0
538.1
688.6
39.8%
55.5
188.2
555.9
71.9
484.0
10.3
473.7
125.1
348.6
2.3
346.4
20.0%
3.4 *
8.5%
-3.4%
11.3%
14.3%
6.8%
-65BPS
27.0%
11.0%
7.4%
4.1%
7.9%
-100.0%
10.2%
8.9%
10.7%
10.1%
10.7%
39BPS
11.3%
FY25
6,813.9
847.6
1,121.5
2,112.6
2,732.2
40.1%
183.2
706.0
2,209.4
267.4
1,941.9
10.3
1,931.6
493.7
1,437.9
7.2
FY24
5,478.1
654.4
902.2
1,712.5
2,209.0
40.3%
208.2
570.0
1,847.2
239.9
1,607.3
20.5
1,586.8
390.4
1,196.4
8.1
1,430.8
1,188.3
21.0%
13.9
21.7%
11.6
(INR Mn)
Y-o-Y
24.4%
29.5%
24.3%
23.4%
23.7%
-23BPS
-12.0%
23.9%
19.6%
11.5%
20.8%
-49.8%
21.7%
26.4%
20.2%
-11.5%
20.4%
-69BPS
20.0%
*Not annualized
8
Key Developments
Strategic Expansion
1
All the New Hubs are now Fully Operational
Kolkata
Krishnanagar
Barasat
Pune
Ambegaon
Kalyani Nagar
Bengaluru
Yelahanka
HSR Layout
10
2
On Track to Commission 2 Hubs in the Core Geography and …
1
On Track to Commission State-of-the-art Hub in Nandyal (AP) in Q2 FY26
▪ 8,000 sq.f.t facility houses an automated lab and
advanced equipment including region’s 1st 3T MRI and 80 slice CT
▪ The strategy aligns with our plan to broaden our
presence by going deeper into tier 2 / 3 geographies of our core markets
2
On Track to Commission State-of-the-art Hub in Khammam (Telangana) in Q2 FY26
▪ Marks our entry into the promising region of
Khammam
▪ 10,000+ sq.f.t facility houses an automated lab and
advanced equipment including a 3T MRI and 160 slice cardiac CT, making it one of the few healthcare set ups in Khammam to offer such high-end services
11
2 … 1 Hub in West Bengal in Q2 FY26 2
3
On Track to Commission State-of-the-art Hub in Kasba (WB) in Q2 FY26
▪ 5,250+ sq.f.t facility houses advanced equipment
including region’s 1st 3T MRI
▪ Kasba is a densely populated urban area, featuring
several prominent hospitals and excellent connectivity
12
Strategic Expansion
Strategic Expansion
Expanding Strategically in Alignment with our Vision
Inorganic Expansion Strategy
• Successfully acquired PH, Pune's largest B2C
integrated diagnostic chain
• This strategic acquisition seamlessly aligns
with our commitment to providing top-notch healthcare services at affordable price, reflecting our shared cultural values
• Operationalized 2 hubs in Ambegaon &
Kalyani Nagar and 2 spokes under Vijaya PH Brand in the last 3 months, following the acquisition
• Aspire to consolidate our presence gradually
by building a denser network
Expansion into Neighbouring State
•
Inaugurated 2 hubs in HSR Layout and Yelahanka, Bengaluru in Q1 FY26
Gurugram
West Bengal
Pune
Telangana
Kalaburagi
AP
Bengaluru
East India Strategy
•
•
•
Inaugurated 2 hubs (Our 3rd and 4th Hub in Kolkata) in Q1 FY26 under the Vijaya brand in Kolkata
On track to operationalize 3 additional hubs by the end of FY26
Employing our proven hub and spoke model, aim to replicate our success in East India by creating a dense network
Core Market Strategy
• Embracing our hub-and-spoke model, we aim to broaden our presence in concentric circles,
strategically reaching Tier 1 and Tier 2 cities within AP and Telangana where our brand is highly esteemed
• Assessing few more lease opportunities for hubs
• On track to launch 2 more hubs in Nandyal and Khammam (AP & Telangana) by Q2 FY26
14
Expansion Plans - Upcoming Hubs and Spokes Centres
Geography
Count & Type
Tentative Timelines for Commencement
Q2 FY26
West Bengal
RoAPT
Hyderabad
1 Hub
2 Hubs
Q2 FY26
H2 FY26
2 Hubs
Q2 FY26
1 Spoke
1 Spoke
Q2 FY26
H2 FY26
3 Hubs
1 Spoke
H2 FY26
2 Hubs
1 Spoke
Total Upcoming FY26
5 Hubs
2 Spokes
15
Company Overview
Strategic Expansion
Vijaya at a Glance
Vijaya Diagnostic is the largest integrated B2C focused diagnostic chain in India with 157 state-of-the-art centres spread across 27 cities & towns
Evolved from a regional player to a player with presence in multiple geographies …
… While retaining its core values of providing Quality, Reliable & Accurate Diagnostic services at Affordable prices
157 Centres
40+ Years of Vintage
17 labs with NABL Accreditation
Founded by Mr. Surendranath Reddy in 1981 and currently led by Ms. Suprita Reddy
27 Cities and towns across India
300+ Doctors
Largest integrated player in South India
Radiologist & Pathologist network
~4.33 Mn Footfalls (1)
Trusted by every Age group
~15.36 Mn Tests (1)
Most preferred Diagnostic Centre
17
1. Footfall and Tests for the 12 months ended 30-Jun-25
Our Journey
1981
1993
1995 2007
2003
2012
2005 2016
▪ Vijaya Diagnostic Centre
incorporated in Hyderabad
▪ Became 1st Independent diagnostic centre in South India to offer PET CT from Wipro GE Healthcare
▪ Recognized as one of the Best Imaging centres in Hyderabad by The Week
▪ Received investment from
Karakoram Limited & Kedaara Capital Alternative Investment Fund – Kedaara Capital AIF1
2020
2006
2008 2019
2010
2018
2013 2021
▪ One of the earliest private
diagnostic service providers to be approved for COVID RT- PCR testing by ICMR*
▪ Awarded Best Diagnostic Centre – India by Times Healthcare Achievers Group
▪ Awarded Brand of the year in diagnostic services by The CEO Magazine and Telangana Healthcare Leadership award
▪ Successfully listed on Indian Stock
Exchanges (NSE* & BSE*)
▪ 1st independent diagnostic centre in Telangana to get Revolution ACT 50 slice CT from Wipro GE Healthcare
2022
2023
2024
2025
▪ Awarded one of the Best Healthcare Brands 2022 by The Economic Times
▪ Won the Healthcare Leadership
Awards 2022
▪ Awarded Pride of India Brands Award – The Best of South Awards 2022
▪ Successfully launched the first center in Kolkata under the "Vijaya“ brand name
▪ Acquired 100% stake in P.H. Diagnostics and forayed into Pune
▪ Awarded Best Brand at ET Edge
Awards 2023
▪ Transitioned to AI Power Pack -
“Augmento”
▪ Awarded Icon in Integrated Diagnostic Services by Times Health Excellence
▪ Recognized as Fastest Growing
Brands at Asian business & Social Forum 2024, Dubai
▪ Forayed into Bengaluru market
by launching 2 hubs in Yelahanka and HSR Layout under the “Vijaya” brand name
* ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange
18
Integrated Diagnostics Player Offering One-Stop Solution
Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience
Complete Range of Diagnostic Services under One Roof
Pathology (1)
61.5 %
Radiology (1)
38.5 %
1. Revenue mix for Q1 FY26
19
Dominant Position in Telangana & AP Markets with a Strong Brand Recall …
Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets
Present in Key Geographies of AP & Telangana
70 (1) %
Hyderabad Revenue Contribution
Nizamabad
Mancherial
Karimnagar
Bhuvanagiri
Hanamkonda
Mahabubnagar
Hyderabad & Secunderabad
Vishakhapatnam
Rajahmundry
Kurnool
Nandyal
Ongole
Nellore
Tirupati
19 (1) %
RoAPT Revenue Contribution
A dense network created across AP & Telangana aids in distributing patient load and offering significantly faster TAT across tests
20
1. For Q1 FY26
… and Driving Geographical Diversification through Strategic Expansion
Hyderabad
Pune
RoAPT
West Bengal
Gurgaon
Kalaburagi
Bengaluru
72%
78%
83%
70%
Geographical Revenue Mix
19%
18%
17% 14%
6%
6%
2%
0%
5%
4%
3%
2%
Q1 FY26
FY25
FY24
FY23
Q1 FY26
FY25
FY24 FY23
Q1 FY26
FY25
FY24 FY23
Q1 FY26
FY25
FY24
FY23
Vijaya is well-placed to attract customers in new geographies due to its integrated offering and strong emphasis on customer experience
21
RoAPT - Rest of AP and Telangana
Boosting Accessibility with Best-in-class Online Services & Home Collections
Enhancing Customer Experience through Seamless Online App, E-Commerce Website and Call Centre Bookings
Elevating Customer Experience through Home Collections
Online Services
Home Collections
Access to reports online & historical medical records
Intuitive(1) & user-friendly interface
Agile customer service team
High Brand salience
High customer stickiness
Organic word of mouth growth
1. Patient can track his / her health trends over time
2. Post Collection
Seamless & Efficient process
Temperature Controlled Logistics
High standards of hygiene maintained
Pre-sealed & sterilized single-use home kit
Reaches Lab within 2 hours (2)
22
Robust Technical Capabilities with State-of-the-art IT Infrastructure
38
9
Advanced Software to Manage Clinical Data
CT Machines
PET CT / Gamma machines
38
MRI Machines
10
300+
Radiologists, Lab Doctors & Physicians
17
NABH Accreditations
NABL Accreditations
Key Suppliers
• Long standing relationship with medical technology vendors
• At the forefront of introducing new tests by adopting the latest medical
technologies
• Among the first diagnostic service provider in South India to offer PET-CT scan
in 2008
Advance Laboratory Information Management System (LIMS)
Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)
Front end IT infrastructure enabling…
Standardization across our operations
Reduce errors due Human Intervention
incidence of Low to
Monitor Operations
Technical
Closely track key performance metrics and maintain the Turn- Around Time (TAT)
Provide Uniform Experience to booking from customers appointments accessing to reports online
Vijaya has been ahead of the curve in getting best-in-class & latest diagnostic equipment in India which has helped in offering high quality services
23
Note: Data above is as at 30-Jun-25
Experienced Board of Directors
Dr. S. Surendranath Reddy Founder & Exec. Chairman
✔ 40+ years of experience ✔ Holds Bachelor’s degree in Medicine and Doctor of Medicine in Radiology
Ms. Suprita Reddy Managing Director & Chief Executive Officer
✔ 22+ years of experience ✔ Awarded Women Leadership Award in Healthcare by ABP
Mr. Sunil Chandra Kondapally Executive Director
S Geeta Reddy Non-Executive Director
✔ 22+ years of experience ✔ Holds Bachelor’s degree in Electrical Engineering from Florida State University
✔ 35+ years of experience ✔ BOD at Sura Agritech, Iffco
Kisan, Namrata Diagnostics, etc.
✔ LLB from Osmania University
Dr. D Nageshwar Reddy Non-Executive Independent Director
✔ Chairman of AIG (1), Hyderabad ✔ Received Padma Shri & Padma Bhushan from Govt of India ✔ D.M (2) from PGIMER Chandigarh
Mr. Shekhar Prasad Singh Non-Executive Independent Director
✔ 40+ years of experience ✔ Ex-Chief Secretary to
Government of Telangana ✔ Retired IAS officer of 1983 batch
Mr. S. Murthy Chavali Non-Executive Independent Director
Dr. Manjula Anagani Non-Executive Independent Director
✔ 35+ years of experience ✔ Ex-CEO - Aurigene Discovery Tech ✔ MBA from IIM, Bangalore & BTech
from IIT, Madras
✔ 25+ years of experience ✔ Clinical Director & HOD - Centre of women & childcare - Care hospitals
✔ Awarded Padma Shri by GOI
1. Asian Institute of Gastroenterology
2. In Gastroenterology
24
Stellar Management Team
Dr. S. Surendranath Reddy Founder & Exec. Chairman
✔ 40+ years of experience ✔ Holds Bachelor’s degree in Medicine and Doctor of Medicine in Radiology
Ms. Suprita Reddy Managing Director & Chief Executive Officer
✔ 22+ years of experience ✔ Awarded Women
Leadership Award in Healthcare by ABP
Mr. Sunil Chandra Kondapally Executive Director
✔ 22+ years of experience ✔ Holds Bachelor’s degree in Electrical Engineering from Florida State University
Mr. Sai Srinivas Lanka Chief Technology Officer
✔ 24+ years of experience ✔ Ex-Wipro Technologies, UnitedHealth Group ✔ MS from BITS Pilani
Mr. Sivaramaraju Vegesna, CFA VP - Operations
✔ 12+ years of experience ✔ Ex-KIMS Hospitals, NSL Sugars ✔ CFA Charter Holder, MBA from Amity University
Mr. Praveen Velmury VP - Sales
✔ 30+ years of experience ✔ Ex-Havells, Vodafone, Nestle ✔ PGDDM from IIM Calcutta
Mr. Hansraj Singh Rajput Company Secretary & Compliance Officer
✔ 10+ years of experience ✔ Ex-Zen Technologies, Gati ✔ LLB & PGDM from NALSAR
Mr. Vishal Gurram GM - Strategy
✔ 12+ years of experience ✔ Ex-Medplus, LetsTransport ✔ MBA from IIM Lucknow &
BTech from NIT Warangal
Mr. Dhiren Gala AGM - Strategy & Investor Relations
✔ 7+ years of experience ✔ Ex-Investec, Axis Capital ✔ MBA from SPJIMR & CA
25
Shareholding Pattern as at 30th June, 2025
Shareholding Pattern as at 30th June, 2025
Others 3.7%
FIIs 19.6%
DIIs 24.1%
Promoter & Promoter Group 52.6%
DIIs: Mutual Funds, AIFs and QIBs FIIs: Hedge Funds, Sovereign Wealth Funds, Foreign MFs, Pension Funds, Trusts and AMCs Others: Retail, Bodies Corporate and others
Key Investors
26
Doctors Connect Program in Q1 FY26
Vijaya Diagnostic organised a webinar on MR imaging in endometriosis and adenomyosis
Vijaya Diagnostic organised a webinar on the Biochemical investigations in female infertility
27
Awards & Accolades
Best Healthcare Brands’ 2025
recognized by ET Edge
Icon in Integrated Diagnostic
Services by Times Health
Excellence 2024 - TS & AP
Most Preferred Workplace for
Women 2024 – 25 recognized
by Marksmen Daily
Most Trusted Brand of India
2024-25 awarded by
Marksmen Daily – 4th edition
Fastest Growing Leaders 2023-
24 awarded at Asian business &
Social Forum 2024, Dubai
Fastest Growing Brands 2023-
24 awarded at Asian business &
Social Forum 2024, Dubai
Best Healthcare Brands’ 2024
Best Brand awarded at ET Edge
recognized by ET Edge
Awards 2023
Excellence In Comprehensive
Diagnostic Care awarded by
ABP Ananda Swasthya Samman
Best Healthcare Brands’
awarded by Economic Times -
2023
Best Healthcare Brands’
awarded by Economic Times -
2022
Most Trusted Brand of India
awarded by Marksmen Daily –
3rd edition
Company of the Year 2021 -
Healthcare presented by
TV9 Network and SAP
Best Healthcare Brands’
awarded by Economic Times -
2021
Leading Diagnostic Chain of
the Year 2021 presented by
Diagnostic Leadership Summit
28
Annexure
Strategic Expansion
State-of-the-art Infrastructure (1/3)
30
State-of-the-art Infrastructure (2/3)
31
State-of-the-art Infrastructure (3/3)
32
Advanced Equipment in Place to Deliver High Quality Services (1/2)
33
Advanced Equipment in Place to Deliver High Quality Services (2/2)
34
Robust Operational Metrics
Diagnostic Centre (Nos)
Footfalls (Mn)
Tests Performed (Mn)
145
151
121
95
80
3.62
3.55
3.18
2.63
4.19
14.79
11.89
9.32
10.05
7.09
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
Test per Footfall (Nos)
Revenue per Test (INR)
Revenue per Footfall (INR)
Impact of COVID-19
3.17
3.35
3.53
2.69
2.57
531
496
1,431
1,276
1,446
1,543
1,627
457
461
461
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
35
Consistent Financial Performance
Revenue
CAGR:16.0%
EBIDTA
CAGR:13.3%
6,814
5,478
4,624
4,592
3,767
2,037
1,820
1,660
2,732
2,209
(INR Mn)
PAT
CAGR:14.1%
845
1,097
846
1,431
1,188
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
EBIDTA Margin (%)
PAT Margin (%)
44.1% 44.1%
39.6%
40.3% 40.1%
22.4% 23.7%
21.7% 21.0%
18.4%
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
Integrated business model with high B2C concentration (~93%) and a strong brand recall has resulted in Industry leading margins
Note: With effect from 01 January 2023, the Company has changed its method of depreciation on all Property, Plant and Equipment from Written Down Value (“WDV") method to Straight Line Method (“SLM"), based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets. Due to the aforesaid change, the PAT for the year Financial year ended March 31, 2023 and Financial year ended March 31, 2024 was higher by Rs 67.7 Mn and Rs 290.8 Mn respectively
36
Sustainable Cash Generation & Increasing Return Ratios
Surplus Cash
2,277
2,466
2,554
(INR Mn)
1,822
1,985
CFO (1) / EBIDTA (%)
90%
78%
77%
83%
82%
FY21
FY22
FY23
FY 24
FY 25
FY21
FY22
FY23
FY24
FY25
RoCE Pre-Tax (2) (%)
RoE (%)
32%
31%
23%
23%
25%
25%
22%
18%
18%
16%
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
1. CFO = Cash flow from Operations
2. ROCE (Pre-tax): PBIT ex Other income / (Networth + Long Term Debt)
37
Consolidated Profit & Loss Account
Particulars
Revenue from operations
Cost of materials consumed
Employee benefits expense
Other expenses
EBITDA
EBITDA %
Other income
Depreciation and amortization expense
EBIT
Finance costs
Profit before tax and exceptional items
Exceptional items
Profit before Tax
Tax expenses
Profit after Tax before Minority Interest
Minority Interest
Profit after Tax
PAT %
EPS – Basic (INR)
FY21
3,767
571
574
962
1,660
44.1%
118
505
1,274
152
1,121
-
1,121
270
851
6
845
22.4%
8.28
FY22
4,624
715
707
1,165
2,037
44.1%
128
527
1,638
165
1,474
-
1,474
367
1,107
10
1,097
23.7%
10.76
FY23
4,592
589
785
1,398
1,820
39.6%
142
617
1,344
209
1,135
-
1,135
283
852
5.8
846
18.4%
8.29
FY24
5,478
654
902
1,712
2,209
40.3%
208
570
1,847
240
1,607
21
1,587
390
1,196
8
1,188
21.7%
11.62
(INR Mn)
FY25
6,814
848
1,122
2,113
2,732
40.1%
183
706
2,209
267
1,942
10
1,932
494
1,438
7
1,431
21.0%
13.95
38
Consolidated Balance Sheet
Assets
Mar-21 Mar-22 Mar-23 Mar-24 Mar-25
Equity & Liabilities
Mar-21 Mar-22 Mar-23 Mar-24 Mar-25
(INR Mn)
NON-CURRENT ASSETS Property, plant and equipment Capital work-in-progress Goodwill Other intangible assets Right of use asset Intangible assets under development Financial assets - Investments - Other financial assets Deferred tax assets Income tax assets Other assets
CURRENT ASSETS Inventories Financial assets - Investments - Trade receivables - Cash and cash equivalents - Bank balances other than Cash and cash equivalents - Loans - Other financial assets Other current assets
3,022 1,358 82 53 6 1,260 12
0 122 61 6 61
4,436 1,966 341 53 14 1,672 1
0 75 89 2 223
5,777 2,940 271 53 22 2,223 6
0 90 83 2 85
7,714 3,785 83 1,192 207 2,235 5
0 113 29 2 62
9,664 4,469 703 1,192 219 2,768 0
0 165 0 12 136
2,388 26
2,698 43
2,757 20
2,113 52
3,073 49
276 64 67
542 98 110
1,390 95 242
1,091 162 222
1,846 148 128
1,876
1,813
922
508
0 52 27
0 51 41
0 36 51
0 31 46
361
0 478 62
EQUITY Equity share capital Instruments entirely equity in nature Other equity Non-Controlling Interest NON-CURRENT LIABILITIES
3,592 45 - 3,547
4,695 102 - 4,593
5,466 102 - 5,364
6,599 102 - 6,497
7,993 103 - 7,890
1,377
1,778
2,406
2,500
3,119
Financial liabilities
- Borrowings - Lease liabilities - Other financial liabilities Provisions Other liabilities Deferred tax liabilities
CURRENT LIABILITIES Financial liabilities - Borrowings - Lease liabilities - Trade payables - Other financial liabilities Income tax liabilities Provisions Other current liabilities
33 1,265 2 77 1 -
0 1,703 0 74 1 -
0 2,330 0 71 5 -
0 2,391 0 106 3 -
0 2,964 0 99 3 53
440
661
662
729
1,625
12 101 222 61 16 7 20
6 126 216 248 9 21 35
0 145 277 140 24 40 36
0 201 329 114 12 32 40
0 232 330 925 35 60 44
TOTAL ASSETS
5,409
7,135
8,534
9,828 12,736
TOTAL EQUITY AND LIABILITIES
5,409
7,135
8,534
9,828 12,736
39
Consolidated Cash Flow Statement
Particulars
Cash Flow from Operating Activities Profit before Tax Adjustment for Non-Operating Items Operating Profit before Working Capital Changes Changes in Working Capital Cash Generated from Operations Less: Direct Taxes paid Net Cash from Operating Activities Purchase and construction of property, plant and building (net) Acquisition of subsidiary Investments (net) Others Cash Flow from Investing Activities Cash Flow from Financing Activities Net increase/ (decrease) in Cash & Cash equivalent Cash & Cash Equivalents at the beginning of the period Cash & Cash equivalents at the end of the period
Surplus Cash
Particulars
Investments* Cash and cash equivalents Bank balances other than Cash and cash equivalents** Less: Deferred Capital Creditors Total
Mar-21
Mar-22
Mar-23
Mar-24
Mar-25
(INR Mn)
1,121 534 1,655 -46 1,609 -312 1,297 -312 - -1,033 47 -1,298 -488 -489 556 67
1,474 572 2,046 -67 1,979 -399 1,580 -1,223 - -127 120 -1,231 -306 44 67 110
1,135 683 1,818 90 1,908 -262 1,646 -1,248 - 734 887 -1,096 -419 131 110 242
1,587 599 2,186 -14 2,172 -339 1,833 -880 -1,475 530 401 -1,423 -445 -36 258 222
1,932 786 2,720 -74 2,644 -399 2,245 -955 - -893 29 -1,819 -520 -94 222 128
Mar-21
Mar-22
Mar-23
Mar-24
Mar-25
335 67 1,876
2,277
542 110 1,813
2,465
1,390 242 922
2,554
1,092 222 537
1,851
1,846 128 843 750
2,067
40
*Current investments + investments with maturity more than 12 months (part of other non-current financial assets)
** Includes all the fixed deposits
Thank You
For further information please contact:
Mr. Dhiren Gala AGM - Strategy & Investor Relations +91 90598 93206
dhiren.g@vijayadiagnostic.in ir@vijayadiagnostic.in
www.vijayadiagnostic.com
Corporate Office : #6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India.